**INTRODUCTION:** Reduction of postoperative venothromboembolism (VTE) has long been identified as a priority by the American Society of Plastic Surgery. Transgender patients are a unique population by virtue of their exposure to cross-sex hormone therapy (CSHT) and a postulated increased risk of VTE. There remains a lack of data and therefore consensus supporting this perceived risk, leading to variations in practice with significant psychosocial implications. With an ever increasing number of gender-affirming surgeries (GASs) performed annually, we sought to examine the risks and incidence correlated with CSHT and elective surgery.

**METHODS:** A retrospective chart review was performed of all patients who underwent GAS at a single-center institution between 2016 and 2019. Demographic information, preoperative assessment including CAPRINI scores, CSHT regimen/duration, practice of preoperative risk reduction, postoperative VTE prophylaxis management, surgery type, and outcomes were examined.

**RESULTS:** Between 2016 and 2018, 850 GAS cases were identified among 706 patients, 249 transmasculine procedures, and 601 transfeminine procedures. Transmasculine surgeries included 92 hysterectomies, 92 mastectomies, 26 metoidioplasties, and 31 phalloplasties. Transfeminine surgeries included 309 primary vaginoplasties, 75 revisional vaginoplasties, 93 breast augmentations, and 48 facial feminization surgeries. The most common CSHT regimen was testosterone intramuscular injection for transmen and oral estradiol with spironolactone for transwomen. Mean postoperative follow-up was 309 days. The mean calculated 2005 CAPRINI score was 3. Subset analysis revealed that 229 cases were performed without CSHT held before surgery and 708 cases were performed with CSHT held 1 week before surgery. All patients had the same postoperative VTE prophylaxis regimen with heparin SQ started on the morning of postoperative day 1. One patient was identified to have had postoperative VTE, a 37-year-old transgender woman presenting 20 days after vaginoplasty with right thigh pain. Extensive lower extremity occlusion required endovascular thrombectomy/thrombolysis and angioplasty. No pulmonary embolus was identified. Other than estradiol therapy (injection) and surgery, no perioperative risk factors were identified.

**CONCLUSION:** Prevention of postoperative VTE remains an important consideration to any surgical intervention. The current literature correlates oral contraceptive use in women and hormone replacement therapy use in postmenopausal women with an increased risk of VTE, including the postoperative setting. Lack of evidence to the contrary with regard to CSHT has resulted in a heterogenous preoperative approach by surgeons. This includes the practice of stopping hormones for weeks to month before surgery, despite the very real psychological burden on patients with gender dysphoria. To date, there has never been an examination of the incidence of postoperative VTE in transgender patients undergoing GAS or the establishment of correlation. Our large single-center experience would suggest that despite the perceived increase in postoperative VTE risk in patients using CSHT, there remains no evidence to support this correlation or the practice of holding CSHT before elective GAS.
